Holding(s) in Company

RNS Number : 3027G

Immupharma PLC

05 June 2013

 

FOR IMMEDIATE RELEASE

5 JUNE 2013

NOTIFICATION OF AVIVA'S MAJOR INTEREST IN SHARES

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm that  its long standing shareholder Aviva plc ("Aviva") and its subsidiaries has notified the Company that it has recently increased its shareholding in ImmuPharma Ordinary Shares to 4,388,986 representing a 5.38% shareholding in the Company.

The full TR1 form is shown at the end of this announcement.

Commenting on the announcement, Richard Warr, Chairman said: "We are pleased to record that Aviva has again demonstrated its support for ImmuPharma, its assets and long term investment profile."

For further information please see the Group's web site, www.immupharma.com, or contact:

ImmuPharma PLC  (www.immupharma.com)
Richard Warr, Chairman	[phone]
Dimitri Dimitriou, Chief Executive Officer	[phone]
Lisa Baderoon, Head of Investor Relations	[phone]
Panmure Gordon	[phone]
Hugh Morgan, Fred Walsh, Hannah Woodley

Notes to Editors

ImmuPharma

ImmuPharma is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need.  ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents.  The Company's most advanced drug candidate, Lupuzor^TM a potential blockbuster drug for Lupus, a chronic autoimmune disease has recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and "Fast Track" designation.  The Company's second potential blockbuster compound in cancer "IPP-204106" is completing a new Phase I/ II clinical trial with the next generation of "polyplexed Nucant".  ImmuPharma was founded and is led by a commercially focused Board and management team with extensive experience.

Recently ImmuPharma announced that it had secured a £50 million, five year Equity Financing Facility ("EFF") with Darwin Strategic Limited ("Darwin"), a majority owned subsidiary of Henderson Global Investors' Volantis Capital ("Henderson Volantis") to fund ImmuPharma's late stage Lupuzor compound.

For more information on ImmuPharma please go to: www.immupharma.com.

For filings with the FSA include the annex
For filings with issuer exclude the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii				Immupharma plc
2. Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights					√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii		Aviva plc & its subsidiaries
4. Full name of shareholder(s)  (if different from 3.):iv		Registered Holder: BNY Norwich Union Nominees  Limited                                   352,153* Chase (GA Group) Nominees  Limited                                2,792,276* Chase Nominees Limited                                   233,259* *denotes direct interest        Chase (GA Group) Nominees  Limited                                  351,098 Chase Nominees Limited       253,918 Vidacos  Nominees Limited    406,282
5. Date of the transaction and date on which the threshold is crossed or reached: v		31 May 2013
6. Date on which issuer notified:		03 June 2013
7. Threshold(s) that is/are crossed or reached: vi, vii		3% to 4% change at Direct Interest Level and <5% to 5% change at Combined Interest Level

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction				Resulting situation after the triggering transaction
	Number of Shares		Number of Voting Rights		Number of shares	Number of voting rights			% of  voting rights x
					Direct	Direct xi		Indirect xii	Direct		Indirect
Ordinary Shares GB0033711010	2,471,621		2,471,621		4,388,986	3,377,688		1,011,298	4.14%		1.24%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument		Expiration date xiii		Exercise/ Conversion Period xiv			Number of voting rights that may be acquired if the instrument is exercised/ converted.			% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date xvii	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	% of voting rights xix, xx
					Nominal	Delta

Total (A+B+C)
Number of voting rights	Percentage of voting rights
4,388,986	5.38%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: ·      Aviva plc (Parent Company) ·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
10. Name of the proxy holder:		See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:	Figures are based the total number of voting rights of  81,532,463.
14. Contact name:	Tracy Weimar, ImmuPharma plc
15. Contact telephone number:	020 7152 4080

 

END

 

 

HOLVZLFBXQFXBBL